Perkin Elmer has announced that its NTD Laboratories subsidiary has relocated its headquarters, prenatal screening laboratory and research and development (RandD) lab to Melville, Long Island.
NTD Laboratories is a provider of prenatal screening for Down syndrome, trisomy 18/13 and open neural tube defects in the US.
The new facility will enable NTD to meet increased demand for advanced prenatal screening technology including the ultra-screen free Beta HCG/PAPP-A/NT Down syndrome screen and other prenatal screening and diagnostics.
The New York Department of Health certified facility will also include a maternal sample bank.
'The Melville facility will offer advanced prenatal monitoring technologies, expanded capacity for analytical services and RandD, and expanded maternal health services,' said Ann-Christine Sundell, president, Genetic Screening, Perkin Elmer.
'For example, NTD will have the capability to translate research in pre-eclampsia to expand maternal health.' Sundell noted that the 22,000ft2 facility will include an information technology system based on the company's Specimen Gate LIMS software used in many US laboratories to handle several hundred thousand bloodspot samples.
